Protection Against Hyperglycemia in Female Nonobese Diabetic Mice Treated with 15-Deoxyspergualin

References

• Tochino Y. The NOD mouse as a model of type 1 diabetes. CRC Crit Rev Immunol 1987; 8: 49–81
   Google Scholar
• Leiter E H, Prochazka M, Coleman D L. Animal model of human disease. The non-obese diabetic (NOD) mouse. Am J Pathol 1978; 28: 380–383
   Google Scholar
• Lampeter E F, Signore A, Gale E AM, Pozzilli P. Lessons from the NOD mouse for the pathogenesis and immunotherapy of human Type I (insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 703–708
   PubMed Web of Science ®Google Scholar
• Laupacis A, Gardell C, Dupre J., Stiller C R, Keown P, Wallace A C, et al. Cyclosporin prevents diabetes in BB Wistar rats. Luncet 1983; i: 10–12
   Google Scholar
• Mori Suko Y., Okudaria M., Matsuba H. I, Tsuruoka A, Sasaki A, et al. Preventive effects of cyclosporin on diabetes in NOD mice. Diabetologia 1986; 29: 244–247
   Google Scholar
• Stiller C R, DupréM, Gent M, Jenner M R, Keown P A, Laupacis A, et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984; 223: 1362–1367
   PubMed Web of Science ®Google Scholar
• Feutren G, Assan R, Karsenty G, DuRostu H, Sirmai J, Papoz L, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of mul-ticentre double-blind trial. Lancet 1986; ii: 119–124
   Google Scholar
• The Canadian-European randomized control trial group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988; 37: 1574–1582
   PubMed Web of Science ®Google Scholar
• Miyagawa J, Yamamoto K, Hanafusa T, Itoh N, Nakagawa C, Otsuka A, et al. Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetes mice. Diahetologia 1990; 33: 503–505
   Google Scholar
• Murase N, Lieberman I, Nalesnik M A, Mintz D H, Todu S, Drash A L, et al. Effect of FK 506 on spontaneous diabetes in BB rats. Diabetes 1990; 39: 1584–1586
   Google Scholar
• Walter P K, Dickneite G, Schlorlemmer H U, Sedlacek H H, Jäger S, Feifel G, Seitz G. Prolongation of graft survival in allogeneic islet transplantation by (-)15-deoxyspergualin in the rat. Diabetologia 1987; 30: 38–40
   Google Scholar
• Thies J C, Walter P K, Zimmerman F A, Dickneite G, Sedlacek H H, Keller H E, Feifel G. Prolongation of graft survival in allogeneic pancreas and liver transplantation by (-)15-deoxyspergualin. Eur Surg Res 1987; 19: 129–134
   Google Scholar
• Ni M, Chan C-C, Nussenblatt R B, Mochizuki M. FR900506 (FK 506) and 15-deoxyspergualin (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis. Autoimmunity 1990; 8: 43–51
   PubMed Web of Science ®Google Scholar
• Takagishi K, Yamamoto M, Maeda K, Nishimura A, Yonemoto K, Hotokebuchi T, et al. Effects of deoxyspergualin on collagen arthritis in mice. Clin Immunol Immunopathol 1990; 56: 81–87
   Google Scholar
• Strandell E, Andersson A, Groth C-G, Sandler S. Effects of (-)15-deoxyspergualin on pancreatic islet B-cell function in vitro and on the development of diabetes after multiple low dose streptozotocin administration. Pharmacol & Toxicol 1989; 65: 114–118
   Google Scholar
• Harada M, Makino S. Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. Diabetologia 1984; 27: 604–606
   PubMed Web of Science ®Google Scholar
• Sandler S, Andersson A. Modulation of streptozotocin-induced insulitis and hyperglycemia in the mouse. Acta Path Microbiol Immunol Scand Sect [A] 1985; 93: 93–98
   Google Scholar
• Jansson L, Sandler S. The influence of cyclosporin A on the vascular permeability of the pancreatic islets and on diabetes by low doses of streptozotocin in the mouse. Virchows Arch A [Pathol Anat] 1988; 412: 225–230
   Google Scholar
• Sandler S, Andersson A, Hellerström C. Inhibitory effects of interleukin 1 on insulin secretion, insulin biosynthesis and oxi-dative metabolism of isolated rat pancreatic islets. Endocrinology 1987; 121: 1424–1431
   PubMed Web of Science ®Google Scholar
• Andersson A. Isolated mouse pancreatic islets in culture: Effects of serum and different culture media on the insulin production of the islets. Diahetologia 1978; 14: 397–104
   PubMed Web of Science ®Google Scholar
• Krebs H A, Henseleit K. Untersuchungen über die Harnstoffbildung im Tierkörper. Hoppe-Seylers Z Physiol Chem 1932; 210: 33–66
   Google Scholar
• Heding L G. Determination of total serum insulin (IRI) in insulin-treated patients. Diabetologia 1972; 8: 260–266
   PubMed Web of Science ®Google Scholar
• Kissane J M, Robins E. The fluorometric measurement of deoxyribonucleic acid in animal tissues with special reference to the central nervous system. J Biol Chem 1958; 233: 184–188
   PubMed Web of Science ®Google Scholar
• Hinegardner R T. An improved fluorometric assay for DNA. Anal Biochem 1971; 39: 197–201
   PubMed Web of Science ®Google Scholar
• Valdivia L A, Monden M, Gotoh M, Nakano Y, Tono T, Mori T. Evidence that deoxyspergualin prevents sensitization and first-set cardiac xenograft rejection in rats by suppression of antibody formation. Transplantation 1990; 50: 132–136
   PubMedGoogle Scholar
• Okubo M, Masaki Y, Inoue K, Hara R, Taka M, Kamata M, et al. Subacute toxicity of (-) 15-deoxyspergualin in BALB/c mice. I. Hematological study. J Toxicol Sci 1989; 14: 237–245
   Google Scholar
• Zhang H M, Inoue K, Masaki Y, Hara R, Kamata K, Okubo M. Subacute toxicity of (-) 15-deoxyspergualin in BALB/c mice. II. Histopathological study. J Toxicol Sci 1989; 14: 247–255
   Google Scholar
• Charlton B, Bacelj A, Slattery R M, Mandel T E. Cyclophosphamide-induced diabetes in NOD/Wehi mice. Evidence for suppression in spontaneous autoimmune diabetes mellitus. Diabetes, 38: 441–447
   Google Scholar
• Fujii H, Takada T, Nemoto K, Yamashita T, Abe F, Fujii A, Takeuchi T. Deoxyspergualin directly suppresses antibody formation in vivo and in vitro. J Antibiotics 1990; 43: 213–219
   Google Scholar
• Waaga A M, Ulrichs K, Krzymanski M, Treumer J, Hansmann M L, Rommel T, et al. The immunosuppressive agent 15-deoxyspergualin induces tolerance and modulates MHC-antigen expression and interleukin-I production in early phase of rat allograft responses. Transplant Proc 1990; 22: 1613–1614
   Google Scholar
• Dickneite G, Schlorlemmer H U, Sedlacek H H, Falk W, Ulricks K, Müller-Ruchholtz W. Suppression of macrophage function and prolongation of graft survival by the new guandinic-like structure. Transplant Proc 1987; 19: 1301–1304
   Google Scholar
• Nerup J, Mandrup-Poulsen T, Mölvig J, Helqvist S, Wogensen L D, Egeberg J. Mechanisms of pancreatic β-cell destruction in type I diabetes mellitus. Diabetes Cure 1988; 11(suppl 1)16–23
   PubMedGoogle Scholar
• Sadelain W JM, Qin H-Y, Lauzon J, Singh B. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 1990; 39: 583–589
   PubMed Web of Science ®Google Scholar
• Bennett J A, Rao S V, Mitchell M S. Systemic BCG activates natural suppressor cells. Proc Natl Acad Sci (USA) 1978; 75: 5142–5144
   PubMed Web of Science ®Google Scholar
• Strandell E, Eizirik D L, Sandler S. Reversal of β-cell suppression in vitro in pancreatic islets isolated from nonobese diabetic mice during the phase preceding insulin-dependent diabetes mellitus. J Clin Invest 1990; 85: 1944–1950
   PubMed Web of Science ®Google Scholar